P093 TWO DOSE-EQUIVALENT, 21-DAYS, SUBCUTANEOUS (S.C.), GLUCAGON-LIKE PEPTIDE 2 (GLP-2) DOSING REGIMENS, 1.0 MG CONTINUOUSLY VERSUS 0.33 MG THREE TIME DAILY (TID), IN THE TREATMENT OF SHORT BOWEL SYNDROME (SBS) PATIENTS